NANOVIRICIDES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.5M | $5.4M | $6.4M | $5.8M | $6.1M | $4.7M | $5.9M | $5.9M |
| SG&A Expense | $4.0M | $3.1M | $2.6M | $2.3M | $2.6M | $3.3M | $2.7M | $3.4M |
| Operating Income | $-9.6M | $-8.5M | $-8.9M | $-8.1M | $-8.7M | $-8.0M | $-8.7M | $-9.3M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | $49.8K | $938 | $5.1K | $85.4K | $93.7K | $0 | $185.3K |
| Pretax Income | — | — | — | $-8.1M | $-8.8M | $-13.4M | $-8.4M | $-8.6M |
| Income Tax Expense | — | — | — | — | — | $0 | $0 | $0 |
| Net Income | $-9.5M | $-8.3M | $-8.6M | $-8.1M | $-8.8M | $-13.4M | $-8.4M | $-8.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 | $-2.39 | $-2.35 | $-0.13 |
| EPS (Diluted) | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 | $-2.39 | $-2.35 | $-0.13 |
| Shares Outstanding (Basic) | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | 0 | 76.9M | 64.9M |
| Shares Outstanding (Diluted) | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | 0 | 76.9M | 64.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |